^
Association details:
| Biomarker: | MET amplification |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | rilotumumab (AMG 102) (c-MET inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
Published date:
09/25/2017
Excerpt:
Median follow-up was 7·7 months (IQR 3·6–12·0) for patients in the rilotumumab group and 9·4 months (5·3–13·1) for patients in the placebo group. Median overall survival was 8·8 months (95% CI 7·7–10·2) in the rilotumumab group compared with 10·7 months (9·6–12·4) in the placebo group (stratified hazard ratio 1·34, 95% CI 1·10–1·63; p=0·003)...Ligand-blocking inhibition of the MET pathway with rilotumumab is not effective in improving clinical outcomes in patients with MET-positive gastric or gastro-oesophageal adenocarcinoma.
Secondary therapy:
cisplatin + capecitabine + epirubicin
DOI:
10.1016/S1470-2045(17)30566-1
Trial ID:
